Ranbaxy Launches Atorvastatin Cholesterol-Reducing Medication Into the
Canadian Healthcare System


    



    
</pre>
<p>MISSISSAUGA, Ontario, <span class="xn-chron">May 20</span> /CNW/ -- Ranbaxy Pharmaceuticals <span class="xn-location">Canada</span> Inc. (RPCI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced that on <span class="xn-chron">Wednesday, May 19th</span>, the company gained approval from Health <span class="xn-location">Canada</span> to market RAN(TM)-Atorvastatin Tablets (atorvastatin calcium), 10 mg, 20 mg, 40 mg, and 80 mg strengths, in the Canadian Healthcare System.  Atorvastatin is a cholesterol-reducing medicine, the generic equivalent of the brand Lipitor®, which has a current market size in <span class="xn-location">Canada</span> of <span class="xn-money">$1.2 billion</span> ($CAD) [IMS-CDH: February 2010].</p>
<p/>
<p>"As a result of our global settlement, Ranbaxy is pleased to announce the immediate launch of RAN(TM)-Atorvastatin.  Atorvastatin is a lipid metabolism regulator marketed under the Lipitor brand, representing the largest selling pharmaceutical brand in <span class="xn-location">Canada</span>," said <span class="xn-person">Paul Drake</span>, President, RPCI.  RAN(TM)-Atorvastatin will be made available to all Canadian patients under the Ranbaxy label, subject to Provincial formulary listings.</p>
<p/>
<p>Ranbaxy Pharmaceuticals <span class="xn-location">Canada</span> Inc. (RPCI) based in Mississauga, Ontario, <span class="xn-location">Canada</span>, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company.  RPCI is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system.</p>
<p/>
<p>Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in 7 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Daiichi Sankyo is a leading global pharma innovator, headquartered in <span class="xn-location">Tokyo</span>, <span class="xn-location">Japan</span>.</p>
<pre>
    

    *Lipitor® is a registered trademark of Pfizer

    
</pre>
<p> </p>
<p> </p>
<pre>
    
    CONTACTS: Charles M. Caprariello     Paul Drake
               Vice President, Corporate
               Communications            President
                                          Ranbaxy Pharmaceuticals Canada,
              Ranbaxy Inc.                Inc.
              (609) 720-5615             (905) 219-8820





    

For further information: For further information: Charles M. Caprariello, Vice President, Corporate Communications, Ranbaxy Inc., +1-609-720-5615 or Paul Drake, President, Ranbaxy Pharmaceuticals Canada, Inc., +1-905-219-8820

Organization Profile

Ranbaxy Pharmaceuticals Canada Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890